Pacira Pharmaceuticals Stock Gross Profit

PCRX Stock

USD 26.51 0.01 0.04%

Pacira Pharmaceuticals fundamentals help investors to digest information that contributes to Pacira Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Pacira Stock. The fundamental analysis module provides a way to measure Pacira Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pacira Pharmaceuticals stock.

	Last Reported	Projected for Next Year
Gross Profit	433 M	454.7 M
Gross Profit Margin	0.64	0.38

Gross Profit is likely to rise to about 454.7 M in 2024, whereas Gross Profit Margin is likely to drop 0.38 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Pacira Pharmaceuticals Company Gross Profit Analysis

Pacira Pharmaceuticals' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current Pacira Pharmaceuticals Gross Profit

393.23 M

Most of Pacira Pharmaceuticals' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pacira Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Pacira Gross Profit Driver Correlations

Understanding the fundamental principles of building solid financial models for Pacira Pharmaceuticals is extremely important. It helps to project a fair market value of Pacira Stock properly, considering its historical fundamentals such as Gross Profit. Since Pacira Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pacira Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pacira Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.96	0.22	0.95	0.32	0.58	0.97	0.96	0.36	0.92	0.86	0.44	0.94	0.63	0.95	-0.03	0.95	0.83	0.88	0.16	0.52	0.88	0.49	0.78
Total Stockholder Equity	0.96		0.22	0.91	0.38	0.6	0.93	0.98	0.39	0.79	0.76	0.25	0.9	0.64	0.97	0.05	0.98	0.81	0.88	0.11	0.33	0.91	0.61	0.88
Current Deferred Revenue	0.22	0.22		0.28	-0.34	0.35	0.24	0.14	0.7	0.23	0.44	-0.08	-0.02	0.29	0.06	0.61	0.22	0.51	0.37	0.56	0.21	0.12	0.35	0.01
Net Debt	0.95	0.91	0.28		0.3	0.61	0.96	0.9	0.45	0.88	0.81	0.3	0.88	0.6	0.88	0.02	0.91	0.84	0.85	0.35	0.41	0.9	0.43	0.73
Retained Earnings	0.32	0.38	-0.34	0.3		0.04	0.29	0.37	-0.42	0.18	-0.07	-0.02	0.51	-0.31	0.4	-0.5	0.36	-0.09	0.02	-0.24	-0.12	0.55	0.3	0.6
Accounts Payable	0.58	0.6	0.35	0.61	0.04		0.67	0.6	0.5	0.54	0.6	-0.12	0.5	0.35	0.57	0.29	0.63	0.74	0.73	0.26	0.1	0.54	0.4	0.48
Long Term Debt	0.97	0.93	0.24	0.96	0.29	0.67		0.94	0.34	0.9	0.82	0.29	0.94	0.61	0.93	-0.08	0.93	0.85	0.86	0.17	0.43	0.86	0.45	0.74
Net Receivables	0.96	0.98	0.14	0.9	0.37	0.6	0.94		0.28	0.81	0.74	0.27	0.95	0.63	0.99	-0.09	0.99	0.79	0.86	0.0	0.35	0.89	0.53	0.87
Short Term Investments	0.36	0.39	0.7	0.45	-0.42	0.5	0.34	0.28		0.32	0.58	0.0	0.04	0.54	0.23	0.88	0.34	0.66	0.58	0.73	0.14	0.29	0.41	0.11
Total Liab	0.92	0.79	0.23	0.88	0.18	0.54	0.9	0.81	0.32		0.93	0.62	0.84	0.62	0.78	-0.07	0.77	0.79	0.85	0.27	0.7	0.77	0.28	0.58
Total Current Assets	0.86	0.76	0.44	0.81	-0.07	0.6	0.82	0.74	0.58	0.93		0.59	0.69	0.72	0.71	0.26	0.72	0.87	0.9	0.36	0.7	0.65	0.42	0.49
Short Term Debt	0.44	0.25	-0.08	0.3	-0.02	-0.12	0.29	0.27	0.0	0.62	0.59		0.36	0.27	0.27	-0.11	0.18	0.18	0.31	0.03	0.86	0.19	-0.06	0.05
Intangible Assets	0.94	0.9	-0.02	0.88	0.51	0.5	0.94	0.95	0.04	0.84	0.69	0.36		0.48	0.95	-0.34	0.91	0.66	0.75	-0.09	0.39	0.87	0.42	0.82
Common Stock	0.63	0.64	0.29	0.6	-0.31	0.35	0.61	0.63	0.54	0.62	0.72	0.27	0.48		0.61	0.28	0.62	0.8	0.82	0.21	0.32	0.55	0.34	0.49
Property Plant Equipment	0.95	0.97	0.06	0.88	0.4	0.57	0.93	0.99	0.23	0.78	0.71	0.27	0.95	0.61		-0.12	0.98	0.75	0.83	-0.07	0.32	0.88	0.55	0.88
Net Tangible Assets	-0.03	0.05	0.61	0.02	-0.5	0.29	-0.08	-0.09	0.88	-0.07	0.26	-0.11	-0.34	0.28	-0.12		-0.03	0.3	0.25	0.58	-0.03	-0.05	0.34	-0.16
Good Will	0.95	0.98	0.22	0.91	0.36	0.63	0.93	0.99	0.34	0.77	0.72	0.18	0.91	0.62	0.98	-0.03		0.81	0.86	0.06	0.3	0.89	0.54	0.88
Long Term Debt Total	0.83	0.81	0.51	0.84	-0.09	0.74	0.85	0.79	0.66	0.79	0.87	0.18	0.66	0.8	0.75	0.3	0.81		0.94	0.4	0.36	0.71	0.5	0.62
Capital Surpluse	0.88	0.88	0.37	0.85	0.02	0.73	0.86	0.86	0.58	0.85	0.9	0.31	0.75	0.82	0.83	0.25	0.86	0.94		0.27	0.44	0.81	0.49	0.71
Long Term Investments	0.16	0.11	0.56	0.35	-0.24	0.26	0.17	0.0	0.73	0.27	0.36	0.03	-0.09	0.21	-0.07	0.58	0.06	0.4	0.27		0.17	0.19	-0.05	-0.13
Short Long Term Debt	0.52	0.33	0.21	0.41	-0.12	0.1	0.43	0.35	0.14	0.7	0.7	0.86	0.39	0.32	0.32	-0.03	0.3	0.36	0.44	0.17		0.22	-0.15	0.08
Net Invested Capital	0.88	0.91	0.12	0.9	0.55	0.54	0.86	0.89	0.29	0.77	0.65	0.19	0.87	0.55	0.88	-0.05	0.89	0.71	0.81	0.19	0.22		0.54	0.88
Net Working Capital	0.49	0.61	0.35	0.43	0.3	0.4	0.45	0.53	0.41	0.28	0.42	-0.06	0.42	0.34	0.55	0.34	0.54	0.5	0.49	-0.05	-0.15	0.54		0.62
Capital Stock	0.78	0.88	0.01	0.73	0.6	0.48	0.74	0.87	0.11	0.58	0.49	0.05	0.82	0.49	0.88	-0.16	0.88	0.62	0.71	-0.13	0.08	0.88	0.62

Click cells to compare fundamentals

Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Competition

Predict Pacira Pharmaceuticals

Gross Profit Over Time

According to the company disclosure, Pacira Pharmaceuticals reported 393.23 M of gross profit. This is 82.47% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The gross profit for all United States stocks is 98.56% higher than that of the company.

Pacira Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pacira Pharmaceuticals' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pacira Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Pacira Pharmaceuticals by comparing valuation metrics of similar companies.

Pacira Pharmaceuticals is currently under evaluation in gross profit category among related companies.

Pacira Fundamentals

	Return On Equity	0.051
	Return On Asset	0.0335
	Profit Margin	0.06 %
	Operating Margin	0.19 %
	Current Valuation	1.54 B
	Shares Outstanding	46.52 M
	Shares Owned By Insiders	1.26 %
	Shares Owned By Institutions	98.74 %
	Number Of Shares Shorted	3.45 M
	Price To Earning	14.34 X
	Price To Book	1.43 X
	Price To Sales	1.85 X
	Revenue	674.98 M
	Gross Profit	393.23 M
	EBITDA	162.9 M
	Net Income	41.95 M
	Cash And Equivalents	316.39 M
	Cash Per Share	6.90 X
	Total Debt	586.04 M
	Debt To Equity	1.10 %
	Current Ratio	3.95 X
	Book Value Per Share	18.72 X
	Cash Flow From Operations	154.65 M
	Short Ratio	7.57 X
	Earnings Per Share	0.89 X
	Price To Earnings To Growth	(3.83) X
	Target Price	46.4
	Number Of Employees	711
	Beta	0.75
	Market Capitalization	1.23 B
	Total Asset	1.57 B
	Retained Earnings	(106.8 M)
	Working Capital	412.61 M
	Current Asset	252.58 M
	Current Liabilities	149.79 M
	Net Asset	1.57 B

About Pacira Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pacira Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacira Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacira Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pacira Pharmaceuticals Investors Sentiment

The influence of Pacira Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Pacira. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Pacira Pharmaceuticals' public news can be used to forecast risks associated with an investment in Pacira. The trend in average sentiment can be used to explain how an investor holding Pacira can time the market purely based on public headlines and social activities around Pacira Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Pacira Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Pacira Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Pacira Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Pacira Pharmaceuticals.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pacira Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pacira Pharmaceuticals' short interest history, or implied volatility extrapolated from Pacira Pharmaceuticals options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pacira Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether Pacira Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacira Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacira Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacira Pharmaceuticals Stock:

How To Invest In Pacira

Details

Is Pacira Stock a good investment?

Details

What is Pacira Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Pacira Pharmaceuticals Piotroski F Score and Pacira Pharmaceuticals Altman Z Score analysis.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Pacira Stock analysis

When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity

Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.291

Earnings Share

0.89

Revenue Per Share

14.603

Quarterly Revenue Growth

0.054

Return On Assets

0.0335

The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pacira Pharmaceuticals Stock Gross Profit

Pacira Pharmaceuticals Company Gross Profit Analysis

Gross Profit

Revenue

-

Cost of Revenue

Current Pacira Pharmaceuticals Gross Profit

Pacira Gross Profit Driver Correlations

Pacira Gross Profit Peer Comparison

Pacira Fundamentals

About Pacira Pharmaceuticals Fundamental Analysis

Pacira Pharmaceuticals Investors Sentiment

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for Pacira Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY